Tech Company Financing Transactions
Synchron Funding Round
Synchron closed a $10 million Series A funding round on 4/5/2017. Investors included Neurotechnology Investors and DARPA.
Transaction Overview
Company Name
Announced On
4/5/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Neurotechnology Investors (Lead Investor)
Proceeds Purpose
The proceeds will allow the company to initiate a first in human clinical trial in 2018 of Stentrode, an investigational technology system with potential to enable paralyzed patients to achieve direct brain control of assistive technologies, such as robotic limbs, exoskeletons and communication aids.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
1999 S. Bascom Ave. 700
Campbell, CA 95008
USA
Campbell, CA 95008
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Synchron, a US based neural interface company, is developing the STENTRODE, the world's first endovascular electrode array. The STENTRODE is a minimally invasive implantable device designed to interpret signals from the brain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Martin Dieck
Chief Executive Officer
Thomas Oxley
Chief Technical Officer
Nicholas Opie
VP - Bus. Development
Rahul Sharma
Browse more venture capital transactions:
Prev: 4/5/2017: SocialFlow venture capital transaction
Next: 4/5/2017: Apto venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs